Earnings summaries and quarterly performance for Ingersoll Rand.
Executive leadership at Ingersoll Rand.
Vicente Reynal
Detailed
Chief Executive Officer and President
CEO
AS
Andrew Schiesl
Detailed
Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary
EH
Elizabeth Hepding
Detailed
Senior Vice President, Corporate Development
KK
Kathleen Keene
Detailed
Senior Vice President, Chief Human Resources Officer
ME
Matt Emmerich
Detailed
Chief Information Officer
MW
Michael Weatherred
Detailed
Senior Vice President PST Segment, Demand Generation and Execution
VK
Vikram Kini
Detailed
Senior Vice President and Chief Financial Officer
Board of directors at Ingersoll Rand.
Research analysts who have asked questions during Ingersoll Rand earnings calls.
AB
Andrew Buscaglia
BNP Paribas
4 questions for IR
Also covers: AME, APH, CGNX +11 more
Andrew Kaplowitz
Citigroup
4 questions for IR
Also covers: ACM, AOS, APG +29 more
Christopher Snyder
Morgan Stanley
4 questions for IR
Also covers: ALH, ALLE, AME +20 more
JS
Jeffrey Sprague
Vertical Research Partners
4 questions for IR
Also covers: ALLE, AME, AYI +23 more
JM
Julian Mitchell
Barclays Investment Bank
4 questions for IR
Also covers: AIRJ, ALLE, AME +26 more
MH
Michael Halloran
Baird
4 questions for IR
Also covers: AOS, CXT, DOV +19 more
NJ
Nathan Jones
Stifel, Nicolaus & Company, Incorporated
4 questions for IR
Also covers: AOS, BMI, CR +20 more
NC
Nigel Coe
Wolfe Research, LLC
4 questions for IR
Also covers: AME, CARR, CNM +28 more
JO
Joseph O'Dea
Wells Fargo & Company
3 questions for IR
Also covers: ALLE, ATMU, AYI +15 more
ND
Nicole DeBlase
BofA Securities
3 questions for IR
Also covers: CTOS, EMR, ETN +13 more
Robert Wertheimer
Melius Research
3 questions for IR
Also covers: ALSN, AME, CAT +12 more
DR
David Raso
Evercore ISI
2 questions for IR
Also covers: CAT, CMI, CNH +11 more
Joseph Ritchie
Goldman Sachs
2 questions for IR
Also covers: ALLE, CARR, CGNX +22 more
SV
Stephen Volkmann
Jefferies
2 questions for IR
Also covers: AGCO, CARR, CAT +20 more
Amit Mehrotra
UBS
1 question for IR
Also covers: CARR, EMR, ETN +8 more
Joe Ritchie
Goldman Sachs
1 question for IR
Also covers: ALLE, ATS, CARR +16 more
Rob Wertheimer
Melius Research LLC
1 question for IR
Also covers: ALSN, AME, CAT +11 more
Recent press releases and 8-K filings for IR.
Ingersoll Rand outlines growth strategy and life science platform
IR
M&A
New Projects/Investments
- Ingersoll Rand is a $7.5 billion revenue company with 27 % EBITDA margin, 17 % free cash flow margin and a $34 billion market cap, delivering 330 % total shareholder return since its 2017 IPO through a mix of equipment and consumable sales and its IRX continuous-improvement system.
- The business is split between Industrial Technologies & Services and Precision & Science Technologies, with 37 % of revenue from consumables and life-science exposure rising from 4 % in 2020 to 18 % in 2024.
- Its Life Science Technologies Platform integrates ILC Dover (acquired June 2024) and other brands into three lines—flow control, biopharma solutions, and medical device solutions—generating 85 % consumables revenue and mapping >90 % of SKUs one-to-one to customer applications.
- In the past year LST completed four tuck-in deals at an average ~10× EBITDA multiple pre-synergies, targeting mid-teens ROIC within three years, and maintains a pipeline of ~100 life-science-focused acquisition prospects.
- The Precision & Science Technologies segment, including LST, currently runs at ~30 % EBITDA margin and aims to achieve mid-30 % margins medium-term through organic growth and integration synergies.
6 days ago
Ingersoll Rand outlines Life Science Technologies platform at JPMorgan Healthcare Conference
IR
M&A
- $7.5 billion revenue company with 27% EBITDA margin, 17% free cash flow margin, and $34 billion market cap; since its 2017 IPO, total shareholder return exceeds 330%.
- Life science exposure grew from 4% in 2020 to ~18% by end-2024, anchored by the Life Science Technologies platform (including June 2024 ILC Dover acquisition) with 85% consumables revenue.
- Disciplined M&A: completed 76 acquisitions in past five years (16 in 2025) at ~9–10× EBITDA pre-synergy, aiming for mid-teens ROIC within three years.
- Organic synergies: integrating IR’s compressors, pumps, containment films, and diagnostics components into small-molecule API and bioprocess workflows to address end-to-end material handling needs.
- Execution model fueled by the proprietary IRX system and employee ownership mindset, delivering 600 bps EBITDA margin improvement over five years and maintaining <2× leverage.
6 days ago
Ingersoll Rand highlights Life Science Technologies Platform at JPM Healthcare Conference
IR
M&A
- $7.5 billion revenue company generating 27% EBITDA and 17% free cash flow margins, with a $34 billion market cap; since its 2017 Gardner Denver IPO and 2020 Ingersoll Rand merger, TSR has been 330%.
- 37% of revenue is consumable aftermarket; the company has delivered high single-digit revenue CAGR and double-digit EPS CAGR, while improving EBITDA margins by 600 bps over five years.
- The Precision and Science Technologies segment, including the Life Science Technologies Platform, serves biopharma, diagnostics, and medical device markets with ~85% consumables revenue and >90% of SKUs tailored one-to-one to customer applications.
- In the past five years, Ingersoll Rand completed 76 acquisitions (16 in 2025) at a pre-synergy average of 9–10× EBITDA, targeting mid-teens ROIC within three years, while maintaining leverage below 2×.
- PST segment operates near 30% EBITDA margins today, with a medium-term goal of reaching mid-30s, driven by integration of pumps, compressors, isolators, and tailored consumables to high-growth trends like ADCs and gene therapies.
6 days ago
Scatec signs landmark PPA in Egypt
IR
New Projects/Investments
- Scatec ASA has signed a 25-year USD-denominated PPA with the Egyptian Electricity Transmission Company for an integrated hybrid system comprising 1.95 GW of solar and 3.9 GWh of BESS, marking the largest solar and battery installation in Africa and the company’s largest investment to date.
- The project is expected to deliver approximately 6,000 GWh of renewable energy annually, with Scatec providing EPC, asset management, and O&M services based on its large-scale hybrid expertise.
- Financial close is anticipated in H2 2026, with further details on capex, EPC scope, and financing to be disclosed, and Scatec inviting additional equity partners.
Jan 11, 2026, 9:07 AM
Ingersoll Rand expands life sciences portfolio with Scinomix acquisition
IR
M&A
- Ingersoll Rand has acquired Scinomix, Inc., a founder-owned lab automation specialist, to bolster its life sciences offerings.
- Scinomix’s solutions for labeling, handling, barcode scanning, and capping improve throughput, accuracy, and traceability across clinical, pharmaceutical, biotech, forensic, agricultural, and genetic testing workflows.
- The company will join the Life Sciences platform within the Precision and Science Technologies segment, enabling more comprehensive end-to-end lab solutions.
- The acquisition was made at an attractive pre-synergy purchase multiple of approximately 10x 2025 Adjusted EBITDA.
Jan 5, 2026, 9:30 PM
Scatec starts commercial operations at Grootfontein solar power plant
IR
New Projects/Investments
- Commercial operation of the 273 MW Grootfontein solar power plant in South Africa commenced under a 20-year PPA.
- The plant is expected to generate 700 GWh of clean energy annually and abate 630,000 tonnes of CO₂.
- Equity ownership is split between Scatec (51%), H1 Holdings (46.5%), and the Grootfontein Local Community Trust (2.5%).
- Scatec will provide operation & maintenance and asset management services to the facility.
Dec 6, 2025, 7:00 AM
Ingersoll Rand acquires Transvac Systems Ltd.
IR
M&A
- Ingersoll Rand has acquired UK-based Transvac Systems Ltd., broadening its ejector technology offerings and packaged solutions in sustainability-focused markets.
- Transvac will join IR’s Industrial Technologies & Services segment, enhancing hybrid ejector systems used in energy recovery, wastewater treatment, and desalination.
- The transaction underscores IR’s strategy of partnering with founder-led engineering firms to drive innovation and was executed at an attractive high single-digit upfront purchase multiple.
Nov 3, 2025, 9:30 PM
Ingersoll Rand reports Q3 2025 results
IR
Earnings
Guidance Update
M&A
- Q3 orders rose 8% year-over-year (organic +2%), with a book-to-bill of 0.99×; year-to-date organic orders are up 2%.
- Q3 adjusted EBITDA was $545 million (27.9% margin) and adjusted EPS was $0.86 (+2% YoY); free cash flow totaled $326 million. Liquidity stood at $3.8 billion and leverage was 1.8×.
- In Q3 the company deployed $249 million on M&A, repurchased $193 million of shares (2.5 million shares) and paid $8 million in dividends; YTD figures include $460 million of M&A spend, $700 million of buybacks, 14 transactions closed and 9 under LOI (including DayBerry Plastics).
- 2025 guidance midpoint revised: adjusted EBITDA to $2.075 billion and adjusted EPS to $3.28 (from $3.40), reflecting tariff timing; pricing actions are expected to flow through in 2026 and Q4 segment margins are guided roughly flat versus Q3.
Oct 31, 2025, 12:00 PM
Ingersoll Rand announces Q3 2025 results
IR
Earnings
Guidance Update
- In Q3, orders increased 8% to $1.942 B, revenue rose 5% to $1.955 B, adjusted EBITDA grew 2% to $545 M (margin of 27.9%, down 70 bps), and adjusted EPS rose 2% to $0.86 per share.
- Free cash flow was $325.5 M (16.6% margin), and total available liquidity stood at $3.8 B, including $1.2 B in cash and $2.6 B under revolving credit.
- Precision & Science Technologies segment delivered $414.5 M in revenue (up 5.3% YoY) with adjusted EBITDA margin of 30.8%, up 80 bps.
- 2025 full-year guidance: revenue outlook unchanged; midpoint of adjusted EBITDA reduced to $2,075 M (from $2,130 M) and adjusted EPS midpoint cut to $3.28 (from $3.40).
Oct 31, 2025, 12:00 PM
Ingersoll Rand reports Q3 2025 results
IR
Earnings
Guidance Update
Share Buyback
- Q3 orders rose 8% YoY (2% organically) with a 0.99x book-to-bill; backlog is up high-teens since end-2024.
- Delivered Q3 adjusted EBITDA of $545 M (27.9% margin) and adjusted EPS of $0.86; free cash flow was $326 M; liquidity stands at $3.8 B with 1.8x leverage.
- ITS orders grew +7% with a 29% EBITDA margin; PST orders grew +11% with a 30.8% EBITDA margin; full-year adjusted EBITDA guidance midpoint raised to $2.075 B.
- Tariff headwind is slightly in excess of $100 M in 2025; price actions implemented with full mitigation expected in 2026.
Oct 31, 2025, 12:00 PM
Quarterly earnings call transcripts for Ingersoll Rand.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more